Conquer Cancer, Israel Cancer Research Fund Announce Recipient of Co-funded 2022 Career Development Award

Vicki Kilpatrick
Dr. Orit Person

Photo above: Dr. Orit Kaidar-Person

ALEXANDRIA, Va. - Conquer Cancer®, the ASCO Foundation, is pleased to announce Orit Kaidar-Person, MD, of Sheba Medical Center as the recipient of the 2022 Conquer Cancer - Israel Cancer Research Fund Career Development Award (CDA). 

Dr. Kaidar-Person’s proposed study entitled “BRILLIANT study: Breast mri-based artificial Intelligence to identify high risk areas in residual breast tissue after mastectomy and reconstruction” aims to develop imaging-based (Breast MRI) artificial intelligence models, using the largest database in Israel from the Meirav Center at Sheba Tel Hashomer. This model will assist to the identification of areas at high risk for cancer recurrence after mastectomy and implant-based reconstruction.  

“This MRI-based model will highlight, on the patient’s breast images, the areas within the reconstructed breast that are at risk for cancer recurrence. This will help guide the selection and the extent of further treatment such as surgery or radiotherapy to decrease the risks for cancer recurrence. Our new technology should, hopefully, improve outcomes of thousands of breast cancer mastectomy patients worldwide by better identification of recurrence risks and improved options for subsequent treatments,” said Dr. Kaidar-Person.  

This is the third year of collaboration between Conquer Cancer and Israel Cancer Research Fund (ICRF) to award a CDA supporting high-quality clinical oncology research by an early-career physician scientist in Israel. The CDA is a three-year, $200,000 grant that provides resources to clinical and translational investigators during their initial years of faculty appointment when funding is especially challenging. The grant period starts on September 1, 2022. 

“ICRF is thrilled to enhance its grants program by collaborating with Conquer Cancer once again.  Our joint effort enables us to expand our funding opportunities to the brightest and most promising cancer investigators in Israel,” noted Beryl Chernov, ICRF National Executive Director. 

About Israel Cancer Research Fund  

ICRF was established in 1975 by a group of scientists, physicians, and philanthropists in the United States and Canada, who sought to enable the world-class, life-saving work by Israel’s  cancer scientists. Today, ICRF is the largest voluntary charitable organization in North America whose sole mission is to support brilliant cancer research in Israel for the benefit of all humankind. ICRF has provided more than $87 million in funding to support the most innovative cancer researchers from leading institutions throughout Israel.